[1] |
Dalbeth, N.; Gosling, A.L.; Gaffo, A.; Abhishek, A. Gout. Lancet. 2021, 397, 1843–1855.
|
[2] |
Chen-Xu, M.; Yokose, C.; Rai, S.K.; Pillinger, M.H.; Choi, H.K. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007-2016. Arthritis Rheumatol. 2019, 71, 991–999.
|
[3] |
Dalbeth, N.; House, M.E.; Horne, A.; Karu, L.; Petrie, K.J.; McQueen, F.M.; Taylor, W.J. The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clin. Rheumatol. 2013, 32, 247–251.
|
[4] |
Dalbeth, N.; Dowell, T.; Gerard, C.; Gow, P.; Jackson, G.; Shuker, C.; Te Karu, L. Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. N. Z. Med. J. 2018, 131, 8–12.
|
[5] |
Dehlin, M.; Drivelegka, P.; Sigurdardottir, V.; Svärd, A.; Jacobsson, L.T.H. Incidence and prevalence of gout in Western Sweden. Arthritis Res. Ther. 2016, 18, 1–7.
|
[6] |
Kuo, C.F.; Grainge, M.J.; Mallen, C.; Zhang, W.Y.; Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann. Rheum. Dis. 2015, 74, 661–667.
|
[7] |
Dubreuil, M.; Neogi, T.; Chen, C.A.; Choi, H.K.; Chaisson, C.E.; Hunter, D.J.; Zhang, Y.Q. Increased risk of recurrent gout attacks with hospitalization. Am. J. Med. 2013, 126, 1138–1141.e1.
|
[8] |
Rothenbacher, D.; Primatesta, P.; Ferreira, A.; Cea-Soriano, L.; Rodríguez, L.A.G. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology. (Oxford). 2011, 50, 973–981.
|
[9] |
Taylor, W.J.; Fransen, J.; Jansen, T.L.; Dalbeth, N.; Schumacher, H.R.; Brown, M.; Louthrenoo, W.; Vazquez-Mellado, J.; Eliseev, M.; McCarthy, G.; Stamp, L.K.; Perez-Ruiz, F.; Sivera, F.; Ea, H.K.; Gerritsen, M.; Scire, C.; Cavagna, L.; Lin, C.; Chou, Y.Y.; Tausche, A.K.; Vargas-Santos, A.B.; Janssen, M.; Chen, J.H.; Slot, O.; Cimmino, M.A.; Uhlig, T.; Neogi, T. Study for updated gout classification criteria: identification of features to classify gout. Arthritis Care Res. 2015, 67, 1304–1315.
|
[10] |
Singh, J.A.; Herbey, I.; Bharat, A.; Dinnella, J.E.; Pullman-Mooar, S.; Eisen, S.; Ivankova, N. Gout self-management in African American veterans: a qualitative exploration of challenges and solutions from patients’ perspectives. Arthritis Care Res. 2017, 69, 1724–1732.
|
[11] |
Kumar, R.; Joshi, G.; Kler, H.; Kalra, S.; Kaur, M.; Arya, R. Toward an understanding of structural insights of xanthine and aldehyde oxidases: an overview of their inhibitors and role in various diseases. Med. Res. Rev. 2018, 38, 1073–1125.
|
[12] |
Gao, J.; Zhang, Z.F.; Zhang, B.; Mao, Q.; Dai, X.W.; Zou, Q.; Lei, Y.; Feng, Y.; Wang, S.J. Novel 3-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-1,2,4-oxadiazol-5(4H)-ones as promising xanthine oxidase inhibitors: design, synthesis and biological evaluation. Bioorg. Chem. 2020, 95, 103564.
|
[13] |
Gliozzi, M.; Malara, N.; Muscoli, S.; Mollace, V. The treatment of hyperuricemia. Int. J. Cardiol. 2016, 213, 23–27.
|
[14] |
Burmaoglu, S.; Ozcan, S.; Balcioglu, S.; Gencel, M.; Ali Noma, S.A.; Essiz, S.; Ates, B.; Algul, O. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents. Bioorg. Chem. 2019, 91, 103149.
|
[15] |
Singh, J.A.; Akhras, K.S.; Shiozawa, A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res. Ther. 2015, 17, 120.
|
[16] |
Hammer, B.; Link, A.; Wagner, A.; Bohm, M. Fatal allopurinol-induced hypersensitivity syndrome in asymptomatic hyperuricaemia. Deut Med. Wochenschr. 2001, 126, 1331–1334.
|
[17] |
Šmelcerović, A.; Tomović, K.; Šmelcerović, Ž.; Petronijević, Ž.; Kocić, G.; Tomašič, T.; Jakopin, Ž.; Anderluh, M. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur. J. Med. Chem. 2017, 135, 491–516.
|
[18] |
Gao, J.; Liu, X.G.; Zhang, B.; Mao, Q.; Zhang, Z.; Zou, Q.; Dai, X.W.; Wang, S.J. Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors. Eur. J. Med. Chem. 2020, 190, 112077.
|
[19] |
Okamoto, K.; Eger, B.T.; Nishino, T.; Kondo, S.; Pai, E.F.; Nishino, T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J. Biol. Chem. 2003, 278, 1848–1855.
|
[20] |
Matsumoto, K.; Okamoto, K.; Ashizawa, N.; Nishino, T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J. Pharmacol. Exp. Ther. 2011, 336, 95–103.
|
[21] |
Hosoya, T.; Sasaki, T.; Hashimoto, H.; Sakamoto, R.; Ohashi, T. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J. Clin. Pharm. Ther. 2016, 41, 298–305.
|
[22] |
Robinson, P.C.; Dalbeth, N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin. Pharmacother. 2018, 19, 1289–1299.
|